Ulcerative Colitis Epidemiology

Ulcerative colitis is one of the two major inflammatory bowel diseases. It affects around one in every 500 people in the United Kingdom.

Gender prevalence

Unlike Crohn’s disease that affects women slightly more frequently than men, Ulcerative colitis seems to affect both sexes equally or may affect men slightly greater than women.

Age of onset

Ulcerative colitis may start at any age. However, it is rare in children under the age of 5. In most cases the symptoms begin to appear when the person is between ages of 10 and 40 years.

Ethnic, geographical and racial prevalence

Ulcerative colitis is most common in white people of European descent, especially those descended from Ashkenazi Jews. It is seen more commonly among people who have lived for generations in Eastern Europe and Russia. The condition is also common in black individuals but is rarer among those of Asian descent.

The reason for higher prevalence in urban areas and in northern developed countries in Western Europe and America compared to rural areas is unknown. However it has been seen that the prevalence and incidence of new cases is on the rise in developing nations as well.

Overall incidence and prevalence of ulcerative colitis

There are no incidence figures available for either ulcerative colitis or Crohn’s disease until the 1930s. Between 1934 and 1944 the incidence rates of Ulcerative colitis were first reported in two studies done retrospectively in Rochester, Minnesota. The studies found that annually there were 6 cases of Ulcerative colitis per 100 000 population. After this the numbers have been on a steady rise both in Europe and in the Americas.

There has been a lack of gold standard criteria for diagnosis, inconsistent assessment of cases and misclassification of the diseases that has made epidemiological studies of these diseases in large populations difficult.

According to the Centers of Disease Control and Prevention (CDC) the worldwide incidence or diagnosis of new cases of Ulcerative colitis varies considerably between 0.5 and 24.5 per 100.000 populations. Overall prevalence of inflammatory bowel disease worldwide is 396 per 100,000 persons. Nearly 1.4 million persons in the United States suffer from these diseases.

Further Reading

Last Updated: Jul 16, 2023

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2023, July 16). Ulcerative Colitis Epidemiology. News-Medical. Retrieved on October 04, 2024 from https://www.news-medical.net/health/Ulcerative-Colitis-Epidemiology.aspx.

  • MLA

    Mandal, Ananya. "Ulcerative Colitis Epidemiology". News-Medical. 04 October 2024. <https://www.news-medical.net/health/Ulcerative-Colitis-Epidemiology.aspx>.

  • Chicago

    Mandal, Ananya. "Ulcerative Colitis Epidemiology". News-Medical. https://www.news-medical.net/health/Ulcerative-Colitis-Epidemiology.aspx. (accessed October 04, 2024).

  • Harvard

    Mandal, Ananya. 2023. Ulcerative Colitis Epidemiology. News-Medical, viewed 04 October 2024, https://www.news-medical.net/health/Ulcerative-Colitis-Epidemiology.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Current and emerging biomarkers in the management of inflammatory bowel disease